A high prevalence of vitamin D insufficiency occurs in persons with HIV-1 infection in the USA and in European countries. [19] [20] [21] [22] Persons recently emigrated from Africa to the USA, Europe, or Australia often have vitamin D insufficiency. [23] [24] [25] [26] Existing data on vitamin D among persons with or without HIV-1 residing in SubSaharan Africa also suggest a high prevalence of vitamin D insufficiency or deficiency. [27] [28] [29] [30] [31] [32] Based on the existing epidemiological and in vitro and in vivo data described above, we hypothesized that a high prevalence of vitamin D deficiency would be found in Zimbabweans with AIDS-KS and that low baseline vitamin D would be associated with the progression of AIDS-KS.
Methods

Study population
The current study was a retrospective analysis of existing data and stored specimens from 90 subjects enrolled in a prospective investigation of the effect of ART in the treatment of AIDS-KS (Clinicaltrials.gov number NCT00834457) at the Parirenyatwa Hospital Kaposi Sarcoma Clinic in Harare, Zimbabwe between June 2003 and May 2005. 3 The study was reviewed and approved by the Medical Research Council of Zimbabwe and the Colorado Multiple Institutional Review Board, and informed consent was obtained from all participants. All participants had KS confirmed by histopathological examination. Other entry criteria included age >18 years, confirmed presence of HIV-1 antibody, hemoglobin >7.5 g/dl, absolute neutrophil count >750 cells/ml, agreement not to participate in a conception process during study participation, ART naïve, no receipt of chemotherapy or radiation therapy 45 days before study entry, and no intention to relocate out of the Harare area for the duration of study participation. Co-formulated abacavir, lamivudine, and zidovudine was initiated in all participants on day 0. Participants were followed for 96 weeks. 
Clinical and immunological/virological outcomes
The stage of KS was assessed using the criteria of both Krigel et al. and the AIDS Clinical Trials Group, as described previously. 3, 33, 34 Clinical response was defined as either complete or partial resolution of clinically apparent KS disease at week 96. Complete resolution was defined as the absence of KS lesions and tumor-related edema for a minimum of 4 weeks, lasting until the end of the follow-up period. Partial resolution was defined as !50% improvement in KS lesions without complete resolution. KS-associated immune reconstitution inflammatory syndrome (KS-IRIS) was defined as any progression of KS occurring 12 weeks after initiation of ART and was associated with an increased CD4+ lymphocyte count of at least 50 cells/ml above the baseline value, before or at the time of documented KS progression. Virological failure was defined as failure to suppress or failure to maintain suppression of the plasma HIV-1 RNA level to <400 copies/ml after week 24. The rainy season was defined as November through April and the dry season as May through October.
Data analyses
Continuous variables are reported as the median and interquartile range (IQR) and categorical variables as the frequency and percentage. Continuous variables were tested with the Mann-Whitney test and categorical variables with the Chi-square test or Fisher's exact test. The relationship between vitamin D and clinical response was described by odds ratio (OR) and 95% confidence interval (95% CI) and tested with a Chi-square or Fisher's exact test. Logistic regression models were used to adjust for possible confounding of HIV-1 viral load and CD4 count in predicting clinical outcomes. Other analyses were considered exploratory and were not corrected for multiple comparisons. Statistical analyses were conducted in SAS v. 9.2 (SAS Institute) and GraphPad Prism (GraphPad Software Inc.), and assumed a twosided significance level of 0.05.
Results
Prevalence of vitamin D insufficiency and study participant characteristics
Baseline serum samples were available for 85 of 90 subjects. Of those with available samples for analysis, the median 25(OH)D was 72.5 nmol/l (IQR 56.3-88.8 nmol/l). Forty-five (53%) subjects had inadequate 25(OH)D and 17 (20%) had 25(OH)D insufficiency. Fourteen subjects died, 11 subjects were lost to follow-up prior to week 96, and 60 subjects completed 96 weeks of observation ( Figure 1 ). Further characteristics of the study population are provided in Table 1 . Those enrolling during the rainy season had higher median 25(OH)D levels (78.75 vs. 62.5 nmol/l, p = 0.01).
Relationship of vitamin D status and clinical outcomes
Twenty-nine subjects were diagnosed with stage 4 KS at study entry and 71 with T1 disease; the median vitamin D in these subjects was 66.5 nmol/l (IQR 55.8-88.8) and 73 nmol/l (IQR 58-90), respectively. The proportion of stage 4 or T1 disease was similar between the 25(OH)D groups, and 25(OH)D levels were similar between persons with earlier and later stages of AIDS-KS, as shown in Table 1 and Table 2 Table 1 ). Baseline CD4+ count and CD4+ cell increase with ART were slightly lower in persons with vitamin D insufficiency, however this did not reach statistical significance (p ! 0.5). HHV-8 viral load in plasma and PBMC were similar between the 25(OH)D groups (Table 1 ). 
Discussion
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A potential limitation of our study is that we studied only the relationship between baseline 25(OH)D and clinical and immunological/virological outcomes. Our analysis would not have captured the impact of changes in 25(OH)D associated with ART initiation or nutritional status that may have occurred during the course of the study. 21 The small sample population and event number may have limited our power to detect significant differences in outcomes (i.e., survival, clinical response, receipt of adjunctive therapy, development of KS-IRIS). Receipt of chemotherapy or radiation therapy was affected by availability. Regardless of these limitations, we found that more than one half of Zimbabweans with KS-AIDS enrolling in our study had insufficient 25(OH)D. While persons with KS-AIDS may not be representative of the majority of HIV-infected Zimbabweans, the mean 25(OH)D level (75.5 nmol/l) of our population is similar to the weighted mean (84.7 nmol/l) of other African populations with and without HIV infection. 23, 24, [28] [29] [30] [31] 46, 47 In summary, despite associations between vitamin D deficiency and severe disease, AIDS, and death, 22, 48 we were unable to demonstrate improved KS-AIDS outcomes in clinical response, need for chemotherapy or radiation, development of KS-IRIS, survival rates, or more favorable immunological response 49 to ART in association with higher levels of vitamin D. Larger studies should investigate longitudinal associations with vitamin D state in persons with AIDS-KS and other malignancies prior to routinely recommending vitamin D replacement. 
